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1. Introduction 87 
Antipsychotics (APs) are used for treatment of psychotic symptoms in patients with 88 
schizophrenic, schizophreniform, schizoaffective, psycho-organic and bipolar disorders [1-4]. 89 
A combination of psychotherapy and pharmacotherapy can improve symptoms significantly. 90 
However, monitoring of these APs in serum or plasma is often recommended. Therapeutic 91 
drug monitoring (TDM) can aid in finding the right therapy, explaining non-response, 92 
pharmacokinetic interactions or poor response [5, 6].  93 
Especially in psychiatric populations, classical venous blood sampling is often experienced as 94 
unpleasant and even frightening. The interest in alternative sampling techniques, like dried 95 
blood spots (DBS), has consequently increased. DBS sampling is a micro-sampling technique 96 
where a drop of capillary blood is spotted on special filter paper. This technique has been 97 
used routinely since the 1960s, when Guthrie described a method to detect phenylketonuria 98 
in newborns [7]. DBS sampling has a lot of advantages, including ease of sampling, less 99 
invasive and inexpensive sampling, transport and storage [8, 9]. Since only very small 100 
volumes of blood are collected (typically between 10 and 80 µl), interest in DBS methods has 101 
increased in the last two decades due to the availability of more sensitive analytical 102 
techniques [8, 10, 11]. 103 
Interest in DBS sampling for TDM has recently increased [11, 12]. DBS methods have been 104 
described for monitoring of e.g. antidepressants, antiretroviral drugs, antibiotics, 105 
antiepileptic drugs, chemotherapeutic agents, antimycotics and immunosuppressants [12]. 106 
Some DBS methods for multiple drugs including one or two APs are already published [13-107 
15]. No analytical method for determination of multiple AP using DBS has been reported yet. 108 
Analyzing multiple APs in one method makes it possible to monitor polymedicated patients 109 
and to analyze clinical samples of different patients containing any of these APs in one batch.  110 
We aimed to develop a fast and easy to perform DBS method for quantification of 16 APs 111 
and 8 metabolites using a highly sensitive ultra-high performance liquid chromatography-112 
tandem mass spectrometry (UHPLC-MS/MS) technique. Selection of these 16 APs was based 113 
on their importance on the worldwide market and includes the newer APs like asenapine, 114 
iloperidone and lurasidone. Metabolites showing pharmacological activity or helping in 115 
interpretation of TDM data were also selected. Since paliperidone (9-hydroxy-risperidone) is 116 
both a parent compound and a metabolite of risperidone, the total amount of compounds 117 
included in the method is 23. Except for bromperidol and levosulpiride, deuterated internal 118 
standard (IS) were used for each individual compound [16]. 119 
 120 
2. Experimental 121 
2.1 Chemicals and reagents 122 
7-hydroxy-N-desalkyl-quetiapine dihydrochloride (7OH-NDA-QUE), 7-hydroxy-quetiapine 123 
(7OH-QUE), amisulpride (AMI), aripiprazole (ARI), asenapine (ASE), bromperidol (BRO), 124 
clozapine (CLO), dehydro-aripiprazole hydrochloride (DARI), haloperidol (HAL), hydroxy-125 
iloperidone (HILO), iloperidone (ILO), levosulpiride (LSUL), lurasidone hydrochloride (LUR), N-126 
demethyl-clozapine (NDM-CLO), N-demethyl-olanzapine (NDM-OLA), olanzapine (OLA), 127 
paliperidone (PAL), pipamperone dihydrochloride (PIP), quetiapine hemifumarate (QUE), 128 
reduced haloperidol (RHAL), risperidone (RIS), sertindole (SER) and zuclopenthixol succinate 129 
salt (ZUC) were purchased from Toronto Research Chemicals Inc. (Toronto, Ontario, Canada).  130 
The stable isotope labelled internal standards (SIL-IS) 7OH-NDA-QUE-d8 dihydrochloride, 131 
7OH-QUE-d8, AMI-d5, ARI-d5, ASE-
13C,d3, CLO-d8, DARI-d8 hydrochloride, HAL-d4, HILO-d4,  132 
ILO-d3, LUR-d8 hydrochloride, NDM-CLO-d8, NDM-OLA-d8, OLA-d8, PAL-d4, PIP-d10 133 
dihydrochloride, QUE-d8 fumarate, RHAL-d4, RIS-d4, SER-d4 and ZUC-d4 succinate salt were 134 
also purchased from Toronto Research Chemicals Inc. (Toronto, Ontario, Canada). 135 
Acetonitrile, acetic acid, formic acid, methanol and methyl tert-butyl ether (ethanol 136 
stabilized) (MTBE) were from Merck (Darmstadt, Germany). All chemicals were of LC quality. 137 
 138 
2.2 Standards 139 
Methanolic stock solutions of 7OH-NDA-QUE, 7OH-QUE, AMI, ASE, BRO, HAL, RHAL, LUR, 140 
LSUL, PIP, QUE, SER and ZUC were prepared at a concentration of 1 mg/ml. ARI, CLO, DARI, 141 
HILO, ILO, NDM-CLO, NDM-OLA, OLA, PAL and RIS stock solutions were prepared in 142 
acetonitrile at a concentration of 1 mg/ml. Working solutions of each analyte (100, 10 and  143 
1 µg/ml) were prepared by further dilution of the stock solutions with acetonitrile.  144 
Methanolic stock solutions of 7OH-NDA-QUE-d8, 7OH-QUE-d8, AMI-d5, ASE-
13C,d3, HAL-d4, 145 
RHAL-d4, LUR-d8, PIP-d10, QUE-d8, SER-d4 and ZUC-d4 were prepared at a concentration of 146 
100 µg/ml. ARI-d8, CLO-d8, DARI-d8, HILO-d4, ILO-d3, NDM-CLO-d8, NDM-OLA-d8, OLA-d8, PAL-147 
d4 and RIS-d4 stock solutions were prepared in acetonitrile at a concentration of 100 µg/ml. 148 
A working solution containing a mixture of all SIL-IS was prepared in acetonitrile by dilution 149 
of the stock solutions. The final concentration of the deuterated compounds ranged 150 
between 5 and 150 ng/ml, i.e. in the range of calibration level 3 or level 4 of the non-151 
deuterated compounds.  152 
The calibration standards consisted of a mixture of the working solutions containing the 23 153 
analytes at 7 concentration levels. The chosen calibration ranges cover both the defined 154 
therapeutic ranges and the supratherapeutic concentrations [5]. The quality control (QC) 155 
standards were also prepared as a mixture from the different working solutions at 3 156 
concentration levels (QC low, QC mid and QC high). All solutions were stored at -20°C. 157 
Twenty µl of the calibration and QC standards were spiked to 180 µl of human whole blood 158 
to yield final concentrations as shown in table 1. Although we realize that addition of 10 % 159 
organic solvent to blood is suboptimal and may affect blood properties to some extent, this 160 
was not problematic as our procedure utilizes complete spots for analysis. 161 
 162 
2.3 DBS sample collection 163 
As known, the hematocrit (HCT) is identified as the single most important parameter 164 
influencing the spread of blood on DBS cards, affecting the spot formation, spot size, drying 165 
time, homogeneity, the robustness and reproducibility of these assays [8, 17, 18]. In order to 166 
overcome this problem, it was decided to analyze the entire spot instead of using discs 167 
generated by punching only a part of the DBS. Hence, all issues concerning the spreading of 168 
blood could be avoided [19]. However, the influence of the HCT on other parameters, like 169 
matrix effects (ME), remained to be investigated [8]. 170 
Patient DBS samples were collected as follows: the preferred finger was disinfected with a 171 
70% isopropanol cloth, air-dried and warmed for a few minutes. With the help of a single-172 
use automatic lancet (Accu-Chek® Safe-T-Pro Plus, Roche Diagnostics, Mannheim, Germany), 173 
the fingertip was pricked. The first drop of blood was wiped off, since it contains an 174 
important amount of tissue fluid [12]. The second drop was collected in a 25-µl precision 175 
capillary ‘end to end’ (Hirschmann Laborgeräte, Eberstadt, Germany). Once entirely filled, 176 
the capillary was placed in the center of  a marked circle on FTATM DMPK-C Cards (GE 177 
Healthcare, Freiburg, Germany) until the capillary was completely emptied. 178 
 179 
2.4 Sample preparation and extraction 180 
Twenty-five µl of whole blood was spotted onto DMPK-C cards. In line with commonly 181 
applied drying times described in literature [12, 19], these were left to dry for at least 3h at 182 
room temperature. The whole DBS was excised and collected into a 2-ml Eppendorf tube 183 
(Eppendorf AG, Hamburg, Germany). Extraction was performed by adding 450 µl of 184 
methanol, 150 µl of methyl tert-butyl ether (MTBE) and 12.5 µl of the IS working solution. 185 
After shaking the samples during 5 min on an Eppendorf MixMate (Eppendorf AG), the 186 
extract was transferred to a 1.5-ml Eppendorf tube and evaporated to dryness under a 187 
gentle stream of nitrogen at 40°C. The samples were reconstituted in 50 µl of aqueous 188 
ammonium acetate (10 mM)/acetonitrile (9:1; v/v), vortexed for 30 s and centrifuged for 2 189 
min at 10 000 x g. After transferring the extracts to an autosampler vial, a volume of 10 µl 190 
was injected into the UHPLC-MS/MS system. 191 
 192 
2.5 Instrumentation and analytical method 193 
Samples were analyzed on an Agilent 1290 Infinity LC system (Agilent Technologies, Santa-194 
Clara, California, U.S.A.) coupled with an Agilent 6460 Triple Quadrupole mass spectrometer 195 
(MS) run in Jetstream® electrospray ionization (ESI) mode. Data were acquired and analyzed 196 
with Masshunter Workstation Software version B.06.00 (Agilent Technologies). The LC 197 
system was optimized for rapid resolution. 198 
Separation was achieved using an Agilent SB C18 reversed phase column (2.1 x 50 mm, 1.7 199 
µm) (Agilent Technologies) with column oven temperature at 40°C. Gradient elution was 200 
performed at a flow rate of 0.5 ml/min with 10 mM aqueous ammonium acetate at pH 3.7 201 
(A) and acetonitrile (B) using the following program: starting conditions 10 % B; increase to 202 
75 % B between 0 and 2.5 min; further increase to 95 % B between 2.5 and 3 min; retain 95% 203 
B between 3 and 4.5 min; go back to initial conditions from 4.6 to 6. 204 
The MS conditions were optimized as follows: Jetstream ESI technology, positive mode, 205 
nebulizer gas: nitrogen, sheat gas temperature: 400°C, sheat gas flow: 12 L/min, nebulizer 206 
pressure: 50 psi, capillary voltage: 3000 V, and nozzle voltage: 0 V. 207 
The MS was operated in dynamic multiple-reaction monitoring (dMRM) mode, monitoring 3 208 
ion transitions for each analyte in their specific retention time (RT) window (RT ± 0.25 min). 209 
The mass spectrometric conditions for each analyte are identical those of a previous method 210 
for simultaneous determination of the same 16 APs and 8 metabolites in serum 211 
(Supplemental data table 1) [16]. 212 
 213 
2.6 Validation 214 
The following validation parameters were investigated according to in-house guidelines, 215 
which are based upon the international guidelines of EMA (European Medicines Agency) and 216 
FDA (Food and Drug Administration)[20, 21], modified by specific recommendations for 217 
forensic and clinical toxicology [22, 23]: selectivity, linearity, precision, accuracy, recovery, 218 
matrix effects, stability and incurred sample reanalysis. 219 
Selectivity was evaluated by analyzing blank blood from eight different sources, two zero 220 
samples (blank blood + mix of SIL-IS) and two samples spiked with only analytes and no SIL-221 
IS. Carryover was tested by injecting the highest concentration of the calibration curve, 222 
followed by two blank injections and should not exceed 20 % of the lower limit of 223 
quantitation (LLOQ) (n=2). 224 
A seven-point calibration curve was analyzed using IS-corrected areas on each of four 225 
consecutive days. At each of these four days, duplicates of QC samples at LLOQ, low, 226 
medium and high concentration levels were analyzed. Intra-, interday-precision and accuracy 227 
were determined using an ANOVA-calculation as described by Wille et al. [23] Accuracy and 228 
precision data were acceptable when the % bias respectively % coefficient of variation (% 229 
CV) was lower than 15 % (20 % for LLOQ). 230 
Extraction recovery (ER) and matrix effects (ME) were determined at two concentration 231 
levels (QC low and QC high) using whole blank blood from six volunteers, spiked before and 232 
after extraction according to the post-extraction addition technique as described by 233 
Matuszewski et al [24]. ME are calculated as the percent ratio of peak areas of the analytes 234 
spiked after extraction and the blood free solution prepared in acetonitrile. ME were also 235 
evaluated at low and high HCT (19.2 and 67.0 %, respectively). Relative ME were calculated 236 
as the percent ratio of the IS corrected peak areas of the analytes spiked after extraction and 237 
the blood free solution. ER is calculated as the percent ratio of the IS corrected peak areas of 238 
the analytes spiked before and after extraction. % CV of the relative ME should not exceed 239 
15 %.  240 
Stability was evaluated at QC low and QC high (n=3) after 1 day, 1 week and 1 month at 241 
different storage conditions (room temperature, 4°C and -18°C). DBS were stored in zip-242 
closure bags with desiccant. Finally, stability of the processed samples on the autosampler 243 
was determined by analyzing the extracts of QC low and QC high (n=3) after 6 and 12 h, 244 
respectively. Concentrations of all stability samples were calculated based on the daily 245 
calibration curves. The concentration of the stability samples had to be within 90-110 % of 246 
the mean of that of the control samples, and the 90 % confidence interval (CI) of the stability 247 
samples had to be within 80-120 % of the mean concentration of the control samples [22, 248 
23]. 249 
Incurred sample reanalysis was performed on DBS samples of 20 different patients with a 250 
time interval of 1 to 3 months between initial analysis and reanalysis. Data were acceptable 251 
when the % difference between the results was within ± 20 % of their mean for two-thirds of 252 
the samples [20]. 253 
 254 
3. Results & discussion 255 
3.1 Filter paper selection, extraction procedure and detection 256 
Two types of filter paper were tested, Whatman 903 paper (GE Healthcare, Freiburg, 257 
Germany) and Whatman FTATM DMPK-C Cards (GE Healthcare). Both filter papers are 258 
cellulose cards not containing protein denaturing agents, which are known to cause ME [18]. 259 
After extraction of samples on Whatman 903 paper, higher matrix effects were seen in 260 
comparison with the DMPK-C cards. Consequently, DMPK-C cards were selected for further 261 
method development.  262 
Different extraction solvents were evaluated: methanol, acetonitrile and MTBE, as well as 263 
mixtures of these solvents: methanol: acetonitrile at 1:1 (v/v), 3:1 (v/v) and 1:3 (v/v) and 264 
methanol: MTBE at 1:1 (v/v), 3:1 (v/v) and 1:3 (v/v). In literature, methanol, acetonitrile or 265 
mixtures of both are preferable for extraction because they cause protein denaturation and 266 
precipitation [12, 25]. Acetonitrile would yield a higher recovery and less matrix effects than 267 
methanol [9]. MTBE was also tested since it was selected as optimal extraction solvent for 268 
our serum method [16]. Highest recoveries were achieved with a 600 µl methanol: MTBE 269 
(3:1, v/v). Water had to be avoided as extraction solvent, since it is known to cause stability 270 
problems for olanzapine [16, 26, 27] and it increases the interference from endogenous 271 
compounds [12, 25].  272 
Chromatographic conditions and MS parameters were adopted from our serum method for 273 
quantification of APs [16]. Only the source parameters of the MS had to be reevaluated in 274 
order to increase sensitivity of the MS. Since absolute amounts in DBS are lower than in 275 
serum, optimal sensitivity of the detector is mandatory. 276 
 277 
3.2 Validation experiments 278 
Analysis of eight different blank samples revealed no interference from endogenous 279 
compounds nor from filter paper components. The response was less than 20 % of the LLOQ 280 
at the mass transitions of the APs and less than 5 % of the response of the IS. For zero 281 
samples, the response of the IS was less than 20 % of LLOQ at the transitions of APs. The 282 
method proved to be highly selective. No carryover was observed. Injecting blanks right after 283 
the highest calibrators yielded signals lower than 20 % of the LLOQ for all compounds. 284 
Linearity was evaluated by analyzing four calibration curves on four consecutive days. 285 
Unweighted and 1/x weighted linear regression were statistically and visually evaluated. 286 
Inclusion of the zero value in the 95 % CI of the y-intercept indicates absence of constant 287 
error, and a correlation coefficient of 0.99 or higher was pursued. If a linear curve without 288 
1/x weighting would be used, standard error estimation would be biased. For all compounds, 289 
linear regression (1/x weighting) provided the best fit, with r2 of 0.99 or higher for 16 of the 290 
23 analytes and a zero value in the 95 % CI for all compounds except for NDM-OLA. In 291 
comparison, unweighted linear regression resulted in an r2 higher than 0.99 for only 9 of the 292 
23 compounds and a zero value in the 95 % CI for only 20 of the 23 analytes.  293 
Heteroscedastiscity was proven for all compounds by plotting residuals versus nominal 294 
concentrations. Consequently, 1/x weighted linear regression was applied for all 295 
compounds. Accuracy was evaluated using EMA criteria, which state that the back-calculated 296 
concentration should be within 15 % of the nominal value (20 % at LLOQ).  This was fulfilled 297 
for all compounds, except for OLA and NDM-OLA and for PIP at LLOQ. All calibration curves 298 
were linear in the proposed range, except for OLA and its metabolite NDM-OLA. These 299 
compounds were not detected at the lowest concentration of the calibration curve and 300 
back-calculated concentrations were often aberrant. The underlying cause likely is the 301 
instability of these compounds in aqueous medium, since the extract was reconstituted in 302 
aqueous ammonium acetate [16, 26, 27]. As a result, OLA and NDM-OLA were excluded from 303 
further analysis.  304 
On the other hand, if a mean calibration curve is generated from all calibration curves, 305 
aberrancies are seen for LUR. As a consequence, daily calibration is necessary for LUR. The 306 
LLOQ, defined as the lowest concentration of the calibration curve, could be accepted for all 307 
analytes, except for PIP. This implicates that PIP concentrations lower than 50 ng/ml (a 308 
subtherapeutic concentration) cannot be quantified reliably. 309 
Precision and accuracy were determined at four concentration levels (LLOQ, QC low, QC mid 310 
and QC high), analyzed in duplicate on four consecutive days. Accuracy (% bias), intraday 311 
precision (repeatability) and interday precision (intermediate precision) were calculated 312 
from data obtained with ANOVA-analysis (Table 2) [23]. Except for PIP at LLOQ and QC low 313 
and for LUR at QC low, all accuracy data were within the acceptance criteria (bias ≤ 15%, for 314 
LLOQ ≤ 20%). Both intraday and interday precision are acceptable when the CV (%) is lower 315 
than 15 % (20 % for LLOQ). Only for LUR, aberrancies were seen for both intraday and 316 
interday precision at QC low and QC mid. EMA criteria were fulfilled for all other 317 
compounds. 318 
An overview of all ME and ER is given in Table 3. The ER (IS corrected) varied between 28.7 % 319 
for 7OH-NDA-QUE and 84.5 % for PIP, with a median ER of 66.4 % for all compounds. Due to 320 
the use of a more apolar extraction solvent, ER was limited but sufficiently high for this 321 
method. The absolute median ME was 66.1 % (range 8.8 to 100.4 %). Ion suppression is seen 322 
when ME are below 100 %, ion enhancement when ME are above 100 %. For most 323 
compounds, a significant amount of ME is seen with the DBS method. However, these ME 324 
are almost completely compensated by the use of SIL-IS (Supplemental data Figure 1). When 325 
calculating the IS corrected ME, a median ME of 98.8 % (range 86.2 to 125.8 %) was 326 
obtained. For all compounds, CV (%) of the IS corrected ME was lower than 8.5 % and 327 
fulfilled the criteria (< 15 %). Besides the DBS, also filter paper may contribute to high ME. 328 
Moreover, both methanol and MTBE are known to extract endogenous blood lipids and 329 
induce a high ME too. Polar lipids like glycerophosphocholines are soluble in methanol, while 330 
non-polar lipids like cholesterol, cholesterol esters and triacylglycerols are soluble in MTBE. 331 
Presence of lipids in the extract can have an influence on sensitivity, selectivity and 332 
reproducibility of results. Lipids would be less extracted when using acetonitrile [9]. 333 
Consequently, high ME are expected when using a combination of both methanol and MTBE. 334 
However, when acetonitrile was used, lower recoveries were seen and ME were comparable 335 
with methanol.  336 
ER and ME values can be influenced by the HCT. HCT levels are normally about 41-50 % for 337 
men and 36-44 % for women [8, 28]. Since ER and ME were tested on blood samples of six 338 
different volunteers, the HCT of these volunteers was determined and were found within 339 
this normal range. According to literature, a range of 28-67 % HCT would  cover the majority 340 
of adult human blood samples [18]. Therefore, ME were also tested on samples with low 341 
(19.2 %) and high HCT (67.0 %). Adjustment of HCT was made by removing or adding plasma 342 
to a whole blood sample of one of the volunteers. No difference was seen between the 343 
calculated ME at low, normal and high HCT (Supplemental data Figure 2).  344 
Stability experiments were conducted in a way that represents the actual storage conditions 345 
and handling of the samples during the study. Stability was evaluated when storing DBS 346 
samples during 1 day, 1 week and 1 month at different storage temperatures (room 347 
temperature, 4°C and -18°C). Results were compared with samples analyzed directly after 348 
drying for 3 h at room temperature (Table 4). All compounds were stable during 1 month at 349 
the 3 storage temperatures. The stability studies revealed no difference between storage at 350 
room temperature, 4°C and -18°C.  351 
Stability of the extracted samples was also evaluated. Extracted samples were measured 352 
after 6 and 12 h while residing in the autosampler at room temperature. The  acceptance 353 
criteria were not fulfilled for DARI, HILO, LSUL, LUR and ZUC at QC low and for 7-OH-NDA-354 
QUE and LUR at QC high. For 7-OH-NDA-QUE, LSUL and HILO, the deviation from the ratio of 355 
means could be accepted, while the 90 % CI did not meet the criteria. Only for LUR, both the 356 
deviation from the ratio of means and the 90 % CI did not meet the criteria. In Figure 1, a 357 
decrease in concentration is only seen for LUR at both QC low and QC high. After 12 h, the 358 
concentration of LUR was decreased with 32.3 % at QC low and 25.2 % at QC high. Since LUR 359 
is not stable in the processed sample, this can explain the aberrancies in linearity, precision 360 
and accuracy. The longer it takes for an extracted sample to be analyzed on the instrument, 361 
the lower the concentration of LUR will be.  362 
Capillary DBS samples from 20 psychiatric patients were reanalyzed within 1 to 3 months 363 
after the initial analysis. These 20 capillary samples contained 52 different antipsychotics 364 
and metabolites. The criterium for incurred sample reanalysis was fulfilled, since the % 365 
difference between the results was within 20 % of their mean for all compounds in all 366 
samples, except for 7-OH-NDA-QUE. 367 
 368 
 369 
 370 
3.3 Clinical application 371 
Applicability of the DBS method was evaluated on samples, collected from patients with 372 
schizophrenia or bipolar disorder, within the framework of a large clinical study. Patients had 373 
to be in ‘steady-state’ condition (reached after 5-7 half-lives of the drug), which was 374 
translated as an unchanged dose of the antipsychotic in the last 7 days before sample 375 
collection. From every patient, we collected capillary DBS samples, as well as serum and 376 
whole blood just prior to the morning dose of the AP (trough or minimal concentration). In 377 
this study, overall, 10 of the antipsychotics and 6 of their metabolites could be quantified in 378 
the DBS samples. Figure 2 illustrates 4 chromatograms of capillary DBS samples from 4 379 
patients treated with one or more AP(s). Patient A was treated with aripiprazole (20 380 
mg/day), patient B with both amisulpride (400 mg/day) and clozapine (500 mg/day), patient 381 
C with risperidone I.V. (62.5 mg/2 ml every 14 days) and patient D was treated with 382 
amisulpride (200 mg/day) and quetiapine (1400 mg/day). As can be seen in Figure 2, all 383 
antipsychotics were found in the DBS samples from these patients. Table 5 shows data for 10 384 
antipsychotics, quantified in serum, blood and DBS from 10 different patients. 385 
Concentrations found in blood and DBS are quite similar. For some compounds, 386 
concentrations in serum differ more, since they are influenced by the blood:plasma(serum) 387 
distribution of the antipsychotics. Obviously, a large dataset, with sufficient coverage of each 388 
of the antipsychotics, is required to confirm the correlation between the different matrices, 389 
together with the clinical interpretation of the results. 390 
 391 
4. Conclusion 392 
The UHPLC-MS/MS method for analysis of APs and metabolites using DBS overall meets the 393 
requirements of both FDA and EMA for 15 out of the 16 APs and 7 out of the 8 metabolites 394 
selected [20, 21]. Only OLA and NDM-OLA were rejected from the method, likely owing to 395 
their instability in the aqueous reconstitution solvent. Since LUR was not stable in the 396 
extracted DBS sample, analysis by UHPLC-MS/MS must be performed as quickly as possible 397 
for this compound. The short run time of our method (6 min) is highly beneficial in this 398 
respect. This DBS method has high potential in TDM of APs and can be a valuable alternative 399 
to the classic venous blood withdrawal currently used for monitoring. 400 
 401 
 402 
 403 
 404 
 405 
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 410 
 411 
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Figure 1 : Stability of the extracted dried blood spot samples, spiked with QC low (A) and QC 506 
high (B), while residing on the autosampler during 12 h (n=4). Stability was calculated as 507 
deviation from fresh samples. 508 
 509 
 510 
Figure 2: Representative chromatograms of capillary DBS samples obtained from 4 patients 511 
treated with multiple APs. MRM transitions of all antipsychotics and their deuterated IS are 512 
presented. (A) ARI and DARI (found concentrations were 184 and 180 ng/ml, respectively); 513 
(B) AMI, CLO and NDM-CLO (found concentrations were 270, 457 and 449 ng/ml, 514 
respectively); (C) PAL and RIS (found concentrations were 12 and 16 ng/ml, respectively); (D) 515 
AMI, QUE, 7OH-NDA-QUE and 7OH-QUE (found concentrations were 147, 152, 14 and 13 516 
ng/ml, respectively). 517 
 518 
 519 
 520 
 521 
Table 1: Dried blood spot concentrations of calibration standards and quality control 522 
samples of all analytes  523 
Analyte Abbreviation Calibrations standards (ng/ml) 
Internal quality control 
samples (ng/ml) 
    L1 L2 L3 L4 L5 L6 L7 QC low QC med QC high 
Haloperidol HAL 0.5 1 2.5 5 10 25 50 1.5 7.5 35 
Reduced haloperidol RHAL 0.5 1 2.5 5 10 25 50 1.5 7.5 35 
Iloperidone ILO 0.5 1 2.5 5 10 25 50 1.5 7.5 35 
Hydroxy iloperidone HILO 0.5 1 2.5 5 10 25 50 1.5 7.5 35 
Asenapine ASE 1 2.5 5 10 25 50 100 3 20 75 
Bromperidol BRO 1 5 10 15 30 60 100 3 25 80 
7-hydroxy quetiapine 7OH-QUE 1 5 10 15 30 60 100 3 25 80 
7-hydroxy N-desalkyl 
quetiapine 
7OH-NDA-
QUE 
1 5 10 15 30 60 100 3 25 80 
N-demethylolanzapine NDM-OLA 1 5 10 15 30 60 100 3 25 80 
Risperidone RIS 1 5 10 25 50 75 150 3 35 100 
Zuclopenthixol ZUC 1 5 10 50 100 150 300 3 75 225 
Paliperidone PAL 1 10 25 50 100 150 300 3 75 225 
Olanzapine OLA 1 10 25 50 100 150 300 3 75 225 
Sertindole SER 5 10 50 100 150 200 400 15 125 300 
Lurasidone LUR 5 25 50 100 250 500 1000 15 200 750 
Pipamperone PIP 10 50 150 300 500 750 1000 30 400 850 
Dehydro-aripiprazole DARI 10 50 100 300 500 750 1000 30 350 850 
Amisulpride AMI 10 50 100 150 300 600 1200 30 250 900 
N-demethylclozapine NDM-CLO 10 50 100 200 500 750 1500 30 350 1150 
Quetiapine  QUE 10 50 250 500 750 1000 1500 30 650 1250 
Aripiprazole ARI 20 50 250 500 750 1000 1500 60 650 1250 
Clozapine CLO 50 100 250 500 750 1000 1500 150 650 1250 
(Levo)sulpiride LSUL 50 100 250 500 750 1000 1500 150 650 1250 
 524 
525 
 526 
Table 2: Accuracy and precision data for all analytes at four concentration levels. 
Analyte LLOQ 
  
QC low 
  
QC mid 
  
QC high 
  
 
Precision 
intraday 
Precision 
interday Accuracy 
Precision 
intraday 
Precision 
interday Accuracy 
Precision 
intraday 
Precision 
interday Accuracy 
Precision 
intraday 
Precision 
interday Accuracy 
  CV (%) CV (%) bias (%) CV (%) CV (%) bias (%) CV (%) CV (%) bias (%) CV (%) CV (%) bias (%) 
7OH quetiapine 7.77 7.77 8.25 8.00 8.00 -8.75 4.55 5.78 -2.1 7.07 7.76 0.80 
7OH-N-desalkyl 
quetiapine 9.29 12.01 16.13 6.75 8.04 -3.04 11.04 11.05 -5.75 10.47 11.48 12.8 
Amisulpride 3.53 3.95 1.00 3.72 4.40 1.54 5.40 5.40 -5.78 4.91 4.95 3.76 
Aripiprazole 4.01 4.65 4.75 3.93 4.88 -0.69 7.50 7.50 -5.89 2.94 4.09 -1.61 
Asenapine 9.24 10.75 11.63 6.37 7.22 -5.25 8.06 8.37 -5.81 2.98 3.87 -2.07 
Bromperidol 2.95 5.89 -2.50 4.80 5.20 -1.96 7.70 7.70 -1.80 2.55 3.60 -0.73 
Clozapine 6.01 6.46 -2.60 3.85 4.06 9.47 5.39 5.39 -7.02 6.13 6.98 2.02 
Dehydro-
aripiprazole 5.39 5.96 10.25 3.93 4.80 6.71 5.58 5.58 -7.00 4.06 4.39 2.79 
Haloperidol 6.56 7.40 2.75 6.02 6.67 1.92 11.22 11.22 -3.60 3.34 4.30 -1.25 
Hydroxy-iloperidone 6.18 6.76 8.50 5.72 5.72 4.17 6.31 6.66 -6.53 2.76 4.49 -0.68 
Iloperidone 10.63 10.63 6.25 5.49 5.60 3.58 4.16 4.16 -3.83 7.20 7.20 3.10 
Levosulpiride 6.87 6.87 -2.47 3.10 3.21 7.29 5.75 5.75 -5.78 3.02 3.92 3.60 
Lurasidone 14.24 16.23 14.70 15.61 16.32 17.33 16.24 16.24 -6.54 12.75 12.75 -3.64 
Norclozapine 5.00 5.00 4.50 3.92 4.05 5.63 8.11 8.11 -7.01 4.35 4.35 0.32 
Paliperidone 4.50 5.35 9.62 3.57 4.14 0.37 7.33 7.33 -5.75 2.36 3.18 1.79 
Pipamperone 18.91 18.91 -20.25 6.79 7.38 15.58 6.69 7.18 2.41 7.77 8.12 -13.15 
Quetiapine 5.03 6.42 6.88 3.47 3.77 0.71 6.46 6.46 -5.03 2.95 3.41 1.78 
Reduced haloperidol 4.03 5.66 3.75 6.79 7.04 4.67 11.02 10.40 -3.97 5.03 5.03 -3.79 
Risperidone 5.80 5.80 5.13 3.28 4.04 2.08 8.91 8.91 -6.93 3.60 4.30 -0.17 
Sertindol 4.18 4.35 12.78 5.38 5.62 1.83 9.98 9.98 -5.08 5.90 6.20 1.10 
Zuclopenthixol 7.51 8.76 -6.50 7.14 7.21 -4.50 8.71 8.71 -7.00 2.92 3.18 -3.36 
 
 
 
 
Table 3: Recoveries, matrix effects and their respective 95% confidence intervals (CI) obtained with dried blood spot samples of different 
sources (n = 6) spiked with ‘QC low’ and ‘QC high’ concentrations. The CV of the internal standard (IS) corrected matrix effects were < 15 % for 
all compounds. 
 
 
 
Recovery (n = 6) 
   
Matrix effects (n=6) 
  
IS corrected matrix effects (n=6) 
   
  
 
QC low  
 
QC high  
 
QC low 
 
QC high 
 
QC low 
  
QC high 
 
  
Analyte mean (median) (%) 95% CI mean (median) (%) 95% CI mean (median) (%) 95% CI mean (median) (%) 95% CI mean (median) (%) 95% CI CV mean (median) (%) 95% CI CV 
7-OH-N-desalkylquetiapine 33.2 (32.6) 28.0 - 38.4 28.7 (27.4) 25.4 - 32.0 8.8 (8.4) 6.9 - 10.7 19.0 (16.7) 12.1 - 25.9 100.7 (95.5) 82.8 - 118.6 8.5 125.8 (130.4) 112.7 - 138.9 5.5 
7-OH-quetiapine 34.2 (33.6) 28.3 - 40.1 31.8 (31.9) 28.6 - 35.0 10.1 (10.1) 7.4 - 12.8 21.5 (18.4) 12.5 - 30.5 98.3 (100.1) 88.1 - 108.5 4.9 112.7 (112.8) 105.9 - 119.8 3.2 
Amisulpride 62.3 (62.1) 61.0 - 63.6 65.0 (64.1) 60.1 - 69.9 91.4 (92.2) 86.6 - 96.2 96.4 (95.8) 91.9 - 100.9 93.2 (94.4) 89.9 - 96.5 1.6 97.5 (98.9) 91.9 - 103.1 2.7 
Aripiprazole 69.6 (70.2) 65.8 - 73.4 70.7 (68.1) 65.7 - 75.7 53.3 (52.3) 44.6 - 62.0 65.3 (67.0) 60.4 - 70.2 93.5 (93.8) 90.7 - 96.3 1.4 97.2 (98.9) 91.1 - 103.3 3.0 
Asenapine 61.8 (51.8) 44.7 - 78.9 63.4 (62.5) 54.5 - 72.3 60.5 (63.9) 54.2 - 66.8 59.4 (59.8) 55.9 - 62.9 99.2 (103.9) 85.4 - 113.0 6.6 97.3 (94.4) 90.3 - 105.3 3.4 
Bromperidol 68.1 (69.7) 64.0 - 72.2 68.0 (67.8) 63.7 - 72.3 57.2 (57.3) 51.6 - 62.8 66.9 (66.1) 61.2 - 72.6 97.5 (98.0) 91.8 - 103.2 2.7 107.2 (109.6) 101.2 - 113.2 2.8 
Clozapine 54.3 (54.0) 52.3 - 56.3 58.8 (58.0) 55.1 - 62.5 52.4 (51.1) 46.9 - 57.9 74.4 (72.2) 68.2 - 80.6 95.8 (95.8) 92.8 - 98.8 1.4 98.4 (99.6) 93.2 - 103.6 2.5 
Dehydro-aripiprazole 63.6 (64.2) 58.6 - 68.6 70.1 (70.2) 66.4 - 73.8 39.3 (37.9) 33.4 - 45.2 52.5 (53.5) 48.8 - 56.2 100.8 (101.5) 96.1 - 105.5 2.2 103.6 (103.9) 98.3 - 108.9 2.5 
Haloperidol 72.3 (73.2) 66.7 - 77.9 70.9 (68.0) 65.3 - 76.5 57.3 (58.3) 54.5 - 60.1 68.8 (67.4) 62.8 - 74.8 97.9 (98.2) 93.7 - 102.1 2.0 110.4 (114.2) 102.0 - 118.8 3.8 
Hydroxy-iloperidone 68.3 (68.3) 66.7 - 69.9 68.1 (68.7) 63.4 - 72.8 84.5 (84.9) 79.9 - 89.1 100.4 (97.5) 93.3 - 107.5 92.6 (91.8) 87.6 - 97.6 2.5 98.3 (97.8) 91.5 - 105.1 3.2 
Iloperidone 69.3 (69.8) 64.7 - 73.9 71.0 (69.9) 65.4 - 76.6 64.7 (64.9) 62.2 - 67.2 77.2 (74.8) 71.0 - 83.4 101.9 (101.1) 99.6 - 104.2 1.1 111.6 (112.3) 104.9 - 118.3 3.0 
Levosulpiride 68.9 (69.4) 66.5 - 71.3 69.9 (68.7) 64.1 - 75.7 91.7 (92.4) 89.5 - 93.8 90.6 (90.2) 88.1 - 93.1 93.5 (93.5) 91.1 - 95.9 1.2 91.7 (93.2) 85.9 - 97.5 2.9 
Lurasidone 44.6 (47.0) 39.2 - 50.0 58.5 (58.6) 54.9 - 62.1 58.4 (59.2) 49.6 - 67.2  62.8 (59.5) 50.3 - 75.3 104.1 (104.8) 95.4 - 112.8 4.1 96.7 (97.2) 87.2 - 106.2 4.6 
N-desmethyl-clozapine 48.4 (48.0) 46.8 - 50.0 49.5 (49.6) 46.6 - 52.4 42.0 (40.6) 36.1 - 47.9 73.3 (70.2) 67.1 - 79.5 95.0 (95.5) 92.4 - 97.6 1.3 105.9 (105.8) 99.8 - 112.0 2.8 
Paliperidone 65.0 (63.3) 60.9 - 69.1 65.0 (63.1) 61.1 - 68.9 82.3 (82.5) 78.0 - 86.6 96.3 (94.5) 91.6 - 101.0 97.1 (97.5) 95.5 - 98.7 0.8 103.7 (104.5) 97.9 - 109.5 2.7 
Pipamperone 64.0 (63.3) 62.2 - 65.8 84.5 (84.9) 81.6 - 87.4 85.8 (86.4) 80.2 - 91.4 95.3 (95.3) 90.5 - 100.1 99.1 (100.0) 96.8 - 101.4 1.1 108.4 (109.5) 102.9 - 114.1 2.5 
Quetiapine 70.2 (70.5) 67.8 - 72.6 72.8 (72.2) 69.3 - 76.3 87.2 (87.6) 81.2 - 93.2 97.9 (97.0) 93.9 - 101.9 94.3 (94.4) 91.9 - 96.7 1.2 97.7 (98.4) 92.7 - 103.7 2.4 
Reduced haloperidol 74.7 (75.4) 68.9 - 80.5 66.4 (65.6) 58.5 - 74.3 83.8 (83.8) 79.2 - 88.4 98.1 (98.6) 93.6 - 102.6 86.2 (86.3) 84.2 - 88.2 1.0 111.1 (114.4) 102.4 - 119.8 3.9 
Risperidone 67.8 (67.4) 66.4 - 69.2 68.5 (66.7) 64.7 - 72.3 89.5 (89.2) 84.7 - 94.3 97.6 (95.9) 93.0 - 102.2 96.6 (97.0) 93.9 - 99.3 1.3 103.4 (105.3) 97.7 - 109.1 2.7 
Sertindole 66.4 (66.0) 60.5 - 72.3 65.2 (65.5) 61.5 - 68.9 55.3 (54.3) 45.4 - 65.2 46.0 (48.2) 40.8 - 51.2 104.0 (104.5) 100.6 - 107.4 1.6 103.7 (105.3) 96.9 - 110.5 3.2 
Zuclopenthixol 62.8 (63.5) 57.1 - 68.5 69.9 (69.5) 63.7 - 76.1 46.6 (47.1) 36.6 - 56.6 42.5 (41.7) 33.7 - 51.3 102.8 (100.8) 97.4 - 108.2 2.6 103.2 (104.3) 93.5 - 112.9 4.6 
* IS used for bromperidol: haloperidol-d4; IS used for levosulpiride: amisulpride-d5 
           
Table 4 : Stability of the analytes in dried blood spots at QC low (n=3) and QC high (n=3) 
after storage at room temperature, 4°C and -18°C for 1 month. Stability was calculated as 
deviation from samples analyzed directly after drying for 3 h at room temperature. 
 
 
QC low (mean %) 
 
QC high (mean %) 
 Analyte 1 m at RT 1 m at 4°C 1 m at -18°C 1 m at RT 1 m at 4°C 1 m at -18°C 
7-OH-N-desalkylquetiapine* 102.1 92.7 97.3 125.5 104.7 99.6 
7-OH-quetiapine 109.4 94.4 106.2 115.9 92.7 100.6 
Amisulpride 117.7 118.7 116.3 116.7 113.8 119.3 
Aripiprazole 109.0 109.9 110.0 104.4 110.3 112.1 
Asenapine 106.3 99.3 90.7 108.0 109.2 109.4 
Bromperidol 111.6 102.7 97.9 108.0 104.6 106.6 
Clozapine 98.5 96.7 100.0 95.8 90.5 93.5 
Dehydro-aripiprazole 108.1 107.1 105.6 113.8 112.0 113.0 
Haloperidol 109.8 110.4 110.5 105.1 108.2 112.1 
Hydroxy-iloperidone 115.5 113.1 108.9 110.0 112.7 121.5 
Iloperidone 109.5 107.2 113.5 110.3 112.5 113.5 
Levosulpiride 111.9 114.1 113.2 119.0 125.1 118.8 
Lurasidone 106.9 106.4 107.1 101.1 108.3 107.0 
N-desmethyl-clozapine 104.1 100.8 107.7 103.9 100.6 111.1 
Paliperidone 110.3 107.8 112.3 116.5 118.0 119.0 
Pipamperone 104.9 106.4 105.9 100.3 105.1 102.2 
Quetiapine 109.1 116.5 113.2 109.4 119.0 111.9 
Reduced haloperidol 103.3 106.0 112.5 103.5 112.2 111.9 
Risperidone 110.9 110.7 112.5 105.7 112.5 107.2 
Sertindole 104.0 115.2 114.5 109.7 112.2 109.3 
Zuclopenthixol 114.4 107.9 110.4 109.4 107.6 112.4 
* stability calculated as deviation from QC low after1 day 
 
 
 
 
 
 
 
 
 
 
Table 5: Serum, whole blood and capillary DBS concentrations of 10 antipsychotics found in samples 
of 10 different patients. 
Antipsychotic Serum concentration (ng/ml) Whole blood concentration (ng/ml) Capillary DBS concentration (ng/ml) 
Amisulpride 213.0 229.2 269.8 
Aripiprazole 363.8 247.0 264.1 
Bromperidol 4.1 4.4 4.7 
Clozapine 484.5 467.1 456.8 
Haloperidol 1.8 1.1 2.0 
Paliperidone 24.8 18.4 20.9 
Pipamperone 136.7 156.2 244.3 
Quetiapine 85.2 57.9 59.8 
Risperidone 19.4 12.3 11.6 
Zuclopenthixol 4.3 4.5 4.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Data Table 1: Mass spectrometric conditions of all analytes including MRM 
transitions, collision energy (CE), qualifier/quantifier ratio, fragmentor voltage (FV), 
retention time (RT) used for UHPLC-MS/MS. 
Analyte Precursor ion (m/z) Product ion (m/z) CE (V) Ratio (%) FV (V) RT (min) 
Amisulpride 370.2 242.0 26 100.0 188 1.0 
  
196.0 42 51.2 
  
  
112.1 22 34.4 
  Amisulpride-d5 375.2 242.0 26 100.0 188 1.0 
  
196.0 42 51.2 
  
  
117.1 26 33.1 
  Aripiprazole 448.2 285.1 22 100.0 228 2.1 
  
98.1 38 44.3 
  
  
176.1 30 41.8 
  Aripiprazole-d8 456.2 293.1 26 100.0 220 2.1 
  
176.0 30 41.6 
  
  
102.1 42 34.5 
  Dehydro-aripiprazole 446.1 285.1 18 100.0 176 2.0 
  
98.1 42 34.5 
  
  
84.1 62 4.5 
  Dehydro-aripiprazole-d8 454.2 293.1 22 100.0 214 2.0 
  
102.1 46 33.2 
  
  
86.2 66 5.2 
  Asenapine 286.1 166.0 34 100.0 172 1.9 
  
229.0 18 100.6 
  
  
215.0 30 63.4 
  Asenapine-
13
C,d3 290.1 229.0 22 100.0 172 1.9 
  
166.0 34 128.6 
  
  
215.0 30 64.0 
  Bromperidol* 420.1 165.0 22 100.0 172 2.0 
  
123.0 46 74.6 
  
  
402.0 14 8.0 
  Clozapine 327.1 270.0 18 100.0 172 1.7 
  
192.0 46 75.4 
  
  
164.0 90 21.9 
  Clozapine-d8 335.2 275.1 22 100.0 172 1.7 
  
192.0 50 80.4 
  
  
164.0 90 35.2 
  N-desmethylclozapine 313.1 192.0 42 100.0 172 1.6 
  
270.0 22 57.3 
  
  
227.0 26 17.2 
  N-desmethylclozapine-d8 321.2 192.0 46 100.0 172 1.6 
  
275.1 22 27.6 
  
  
227.0 30 13.8 
  Haloperidol 376.2 165.0 22 100.0 172 1.9 
  
123.0 42 122.1 
  
  
95.1 82 53.3 
  Haloperidol-d4 380.2 165.0 22 100.0 172 1.9 
  
123.0 42 113.2 
  
  
95.1 82 48.2 
  Reduced haloperidol 378.2 149.0 26 100.0 166 1.7 
  
109.0 58 61.4 
  
  
342.1 18 11.7 
  Reduced haloperidol-d4 382.2 149.0 26 100.0 166 1.7 
  
109.0 54 61.4 
  
  
346.1 22 12.1 
  Iloperidone 427.2 261.1 26 100.0 196 1.9 
  
190.0 42 83.4 
  
  
233.1 30 76.1 
  Iloperidone-d3 430.2 261.1 26 100.0 196 1.9 
  
190.0 42 80.0 
  
  
233.1 30 73.6 
  
Hydroxy-iloperidone 429.2 261.1 18 100.0 196 1.7 
  
190.0 42 33.2 
  
  
233.1 30 30.2 
  Hydroxy-iloperidone-d4 433.3 261.1 18 100.0 196 1.7 
  
190.0 42 45.8 
  
  
233.1 30 33.9 
  Lurasidone 493.3 166.1 42 100.0 260 2.7 
  
120.1 66 40.2 
  
  
177.0 46 35.3 
  Lurasidone-d8 501.3 166.1 46 100.0 260 2.7 
  
120.1 66 41.9 
  
  
181.6 46 4.8 
  Levosulpiride* 342.2 112.1 22 100.0 188 0.5 
  
110.1 42 30.0 
  
  
214.0 30 20.0 
  Olanzapine 313.2 256.0 18 100.0 176 0.9 
  
198.0 42 28.0 
  
  
169.0 42 14.4 
  Olanzapine-d3 316.2 256.0 18 100.0 176 0.9 
  
198.0 42 27.7 
  
  
169.0 46 15.8 
  N-desmethylolanzapine 299.1 198.0 38 100.0 176 0.8 
  
256.0 22 83.5 
  
  
213.0 26 63.3 
  N-desmethylolanzapine-d8 307.2 198.0 38 100.0 176 0.8 
  
213.0 26 56.0 
  
  
169.0 42 40.5 
  Paliperidone 427.2 207.1 26 100.0 176 1.4 
  
110.0 46 26.2 
  
  
82.1 58 7.3 
  Paliperidone-d4 431.2 211.1 26 100.0 176 1.4 
  
114.1 46 24.8 
  
  
179.0 46 3.0 
  Pipamperone 376.2 165.0 26 100.0 166 1.3 
  
123.0 50 69.6 
  
  
291.1 14 35.9 
  Pipamperone-d10 386.3 165.0 26 100.0 166 1.2 
  
123.0 54 67.8 
  
  
291.1 14 40.5 
  Quetiapine 384.2 253.0 18 100.0 172 1.8 
  
221.1 38 52.0 
  
  
279.1 22 15.8 
  Quetiapine-d8  392.2 226.1 38 100.0 172 1.8 
  
257.7 22 69.2 
  
  
286.1 22 46.7 
  7-hydroxy quetiapine 400.2 269.0 18 100.0 172 1.1 
  
237.1 42 20.9 
  
  
295.0 22 14.2 
  7-hydroxy quetiapine-d8 408.2 274.1 22 100.0 196 1.1 
  
302.1 26 25.9 
  
  
241.1 42 24.6 
  7-hydroxy N-desalkyl quetiapine 312.1 226.0 26 100.0 172 1.2 
  
164.0 62 98.5 
  
  
208.0 38 72.5 
  7-hydroxy N-desalkyl quetiapine-d8 320.2 226.0 26 100.0 172 1.2 
  
164.0 62 79.7 
  
  
208.0 42 45.0 
  Risperidone 411.2 191.1 26 100.0 188 1.5 
  
82.1 66 8.3 
  
  
110.0 54 7.3 
  Risperidone-d4 415.3 195.1 26 100.0 188 1.5 
  
73.2 66 7.4 
  
  
114.1 54 6.8 
  Sertindole 441.2 113.1 30 100.0 188 2.4 
  
71.2 54 13.6 
  Sertindole-d4 445.2 117.1 34 100.0 188 2.4 
  
73.2 58 15.1 
  Zuclopenthixol  401.2 230.9 38 100.0 188 2.4 
  
221.0 58 94.2 
  
  
169.0 42 82.8 
  Zuclopenthixol-d4 405.2 221.0 58 100.0 188 2.4 
  
231.0 34 94.9 
  
  
104.1 26 76.8 
  
* IS used for bromperidol: haloperidol-d4; IS used for levosulpiride: amisulpride-d5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental data Figure 1: Left: Mean absolute ME and mean IS corrected ME obtained by 
extraction of dried blood spots containing blank whole blood spiked with QC low (n = 6). 
Right: Mean absolute ME and mean IS corrected ME obtained by extraction of dried blood 
spots containing blank whole blood spiked with QC high (n = 6). The vertical bars represent 
the 95 % confidence interval. Analytes in the x-axis are sorted based on the elution 
sequence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental data Figure 2: Absolute and IS corrected ME obtained by extraction of dried blood 
spots containing blank whole blood with low (19.2 %), normal (range 36.0-50.0 %) and high 
hematocrit (67.0 %) spiked with QC low and QC high. 
  
